Breast cancer
Conditions
Interventions
Intervention Group:The patient received palbociclib (125 mg/d, qd, d1-d21,28d/cycle)
anlotinib (12 mg/d, qd, d1-d14,21d/cycle)
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Histologically or pathologically confirmed HR+, HER2- advanced breast cancer. 2. Age =18 years old and =75 years old. 3.ECOG physical status score 0-2. 4. Expected survival period =3 months. 5. Have not received anlotinib treatment in the past. 6. Have received a CDK4/6i treatment (other than palbociclib) in the past, and the disease has progressed. 7. At least one measurable objective lesion (extraskeletal) according to RECIST 1.1 criteria
Exclusion criteria
Exclusion criteria: 1. Have received palbociclib or anlotinib treatment in the past; 2. Those who are known to have a history of allergies to the drug components of this regimen; have a history of immunodeficiency, including positive HIV testing, or suffer from other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation; 3. Any known liver disease, including infectious diseases with active infection, autoimmune liver disease and sclerosing cholangitis; 4. Pregnant, lactating female patients or patients planning to become pregnant during the study; 5. Have serious heart disease; 6. Have a history of other malignant tumors (except those that have been cured); 7. Other circumstances in which the researcher deems it inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival;Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Disease control rate;Duration of remission;Safety and Tolerability; | — |
Countries
China
Contacts
Public ContactHou Lingmi
Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed